WASHINGTON (Reuters) – Merck & Co’s experimental insomnia drug is safe and effective at the lower of two doses studied but not at the higher, a panel of medical experts said on Wednesday.
The panel, which advises the U.S. Food and Drug Administrati…
(Reuters) – Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.
LONDON (Reuters) – British farmers will be the first in Europe to get a vaccine against Schmallenberg virus, a new livestock disease that hit the continent in 2011.
Britain’s Department for Environment, Food and Rural Affairs said on Tuesday that MSD A…
(Reuters) – Merck & Co’s experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company’s proposed dosing levels.
The reviewers posted their comme…
Multinational drug companies, like other businesses, see Africa as an emerging market with tremendous opportunities and challenges, and that was a backdrop to Thursday’s announcements of two programs designed to deliver more medicine and better health car…Read This Article
LONDON (Reuters) – Drugmakers Merck and GlaxoSmithKline have cut the price of cervical cancer shots in a deal that will deliver them to poor countries for less than $5 a dose.
The new record low price for human papillomavirus (HPV) vaccines should mea…
(Reuters) – The U.S. Food and Drug Administration approved a Merck & Co cholesterol lowering pill that combines a generic version of Pfizer Inc’s Lipitor with its own Zetia, Merck said on Friday.
The new combination drug will be sold under the bran…
(Reuters) – Drugmakers Pfizer Inc and Merck & Co Inc said they would jointly develop Pfizer’s experimental type 2 diabetes drug, ertugliflozin, and expect late-stage trials to start later in 2013.
Pfizer has so far received $60 million in upfront a…
April 24 (Reuters) – U.S. regulators have granted Merck & Co’s experimental treatment for advanced melanoma a “breakthrough therapy” designation, which could speed development and regulatory review of the product.
The medicine, whose chemical name …
CHICAGO (Reuters) – A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company resea…Read This Article
MUMBAI (Reuters) – A unit of U.S. drugmaker Merck & Co sued India’s Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
The action comes a day after Swiss drugmaker Novartis AG lost a landmark court ruling over pate…
Merck & Co. said Friday that a drug designed to help patients coming out of anesthesia after surgery will require three more months of review by the U.S. Food and Drug Administration.
Sugammadex sodium is an injectable drug that reverses the muscle…
(Reuters) – Pharmaceutical company Merck & Co Inc said on Tuesday an independent monitoring board had allowed it to continue with a large trial assessing the safety and effectiveness of its Vytorin cholesterol treatment.
The panel’s decision sugges…
Merck, known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role since 2003. To ensure a seamless transition, Dr. Perlmutter and Dr. Kim will work closely together for an initial period, after which Dr. Kim will remain with the company as an advisor until his retirement in August.Read This Article
NEW YORK (Reuters Health) – People who take a certain type of diabetes drug to lower blood sugar levels may be at an increased risk of developing an inflamed pancreas, according to a new study.
Glucagonlike peptide 1(GLP-1) therapies that include exenatide – marketed as Byetta by an alliance between Bristol-Myers Squibb and AstraZeneca – and sitagliptin – marketed as Januvia by Merck – have been linked to pancreatitis before in studies on animals and small groups of patients, said the study’s lead author.
“New therapies and risks are only evaluated when studies are done. We need to know (the drugs) are effective in lowering blood sugar, but we also need to know about risks,” said Dr. Sonal Singh, from the Johns Hopkins University School of Medicine in Baltimore.
Pancreatitis, which can cause life-threatening complications, is rare but more common in people with type 2 diabetes. Singh said pancreatitis occurs in about three of every 1,000 diabetes patients.
The U.S. Centers for Disease Control and Prevention estimates that there are about 19 million Americans diagnosed with diabetes, and another 7 million who have the disease but don’t know it yet.
In people with type 2 diabetes, the body doesn’t produce enough insulin or is resistant to what it does produce.
For the new study, published in JAMA Internal Medicine, the researchers used data on 1,269 diabetes patients between the ages of 18 and 64 years old, who were admitted to U.S. hospitals with pancreatitis in 2005 through 2008.
They compared those to 1,269 other diabetes patients who were similar, but were not hospitalized with pancreatitis.
Overall, they found 87 of the diabetes patients with pancreatitis were taking GLP-1 therapies, compared to 58 of the diabetes patients without pancreatitis.
Singh told Reuters Health that the findings show the drugs are linked to a doubling of the risk of pancreatitis – about six cases per 1,000 diabetics.
“I won’t say you should be alarmed about the findings, but it’s something you should consider,” he said.
Dr. Aaron Cypess, a staff endocrinologist in the clinic of the Joslin Diabetes Center in Boston, said the new study will not change how he treats patients, but it may influence him to go over his patients’ risk factors for pancreatitis.
“For me personally it’s not going to change my practice pattern in terms of stopping the drugs, but we may revisit whether you’re showing any of the risk factors,” said Cypess, who was not involved with the new study.
In a joint statement, the American Diabetes Association and the American Association of Clinical Endocrinologists also said the new findings should not change how doctors treat diabetes patients.
“The analysis is a retrospective study using data from an administrative database. This type of analysis is not considered as robust as a prospective randomized controlled clinical trial, the gold standard for evaluating treatments,” the organizations wrote in the statement.
They continue that there are nine of those “gold standard” trials in the works that should provide answers soon.
The current study also had limitations, including that the diabetes patients hospitalized with pancreatitis tended to lead a less healthy lifestyle than those who did not have the condition.
In a commentary, Belinda Gier and Dr. Peter Butler from the University of California, Los Angeles, write supporters say the drugs are safe and offer some advantages over older medications.
Currently, the labels for Januvia and Byetta carry warnings that there have been reports of pancreatitis in people taking the drugs.
Other side effects of Byetta include nausea and other stomach issues. For Januvia side effects also include respiratory infections and headaches. Cypess told Reuters Health both drugs are still protected by patents and can be expensive.
Representatives from Merck and Bristol-Myers Squibb said they – along with drug regulators – actively monitor reports of adverse events in users of their drugs, and have not found evidence showing the drugs cause pancreatitis.
SOURCE: http://bit.ly/YJFiEm JAMA Internal Medicine, online February 25, 2013.
Copyright (2013) Thomson Reuters. Click for restrictions
Read This Article